Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Pancreatic Neoplasms 4Resectable Pancreatic Cancer 1Prostatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma 1

Interventions

Cyclophosphamide 23Cyclosporine 17Busulfan 16fludarabine phosphate 14Radiotherapy 12Mycophenolic Acid 12Cord Blood Stem Cell Transplantation 12Antilymphocyte Serum 12Peripheral Blood Stem Cell Transplantation 11Whole-Body Irradiation 10Methotrexate 8Methylprednisolone 7Tacrolimus 6Filgrastim 6Melphalan 5fludarabine 4sargramostim 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cytarabine 3Cyclosporins 3merphos 2Transplantation 2Thiotepa 2Thalidomide 2Arsenic Trioxide 2vatalanib 1paricalcitol 1lintuzumab 1gamma-Globulins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia, Refractory × paricalcitol × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡